CompletedNot Applicable

Couples ART Adherence Intervention for PWID in Kazakhstan

Kazakhstan132 participantsStarted 2020-10-26

Plain-language summary

The fastest growing HIV epidemics globally are driven by injection drug use, but only a small percentage of HIV-positive people who inject drugs (PWID) have achieved viral suppression. The proposed project will adapt a couple-based antiretroviral therapy (ART) adherence intervention for PWID and assess the feasibility and acceptability of conducting dried blood spot testing to objectively measure ART adherence as part of an intervention in a clinical setting. This project advances HIV intervention science by providing an intervention that leverages social support within the dyad to improve ART adherence among PWID, which could lead to increased viral suppression, thus decreasing HIV transmission and HIV-related morbidity and mortality.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. both partners are ≥18 years old,
✓. both identify each other as their primary sexual partner (e.g. spouse, girlfriend/boyfriend, regular sexual partner),
✓. the relationship has existed at least 3 months,
✓. both report feeling safe participating with their partner in the study,
✓. neither reports any severe physical or sexual violence perpetrated by the other partner in the past year,
✓. both are able to provide informed consent and follow study procedures, and
✓. both are fluent in Russian.

Exclusion criteria

✕. unable to provide informed consent,
✕. unwilling or unable to participate in study procedures,
✕. any condition that, in the opinion of the principal investigator and research staff, would make participation in the study unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.

What they're measuring

Adherence Rate to Antiretroviral Therapy

Timeframe: Day 1 to Day 180 (daily)

Trial details

NCT IDNCT03555396

SponsorColumbia University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2023-03-09

Results submitted2024-06-05

View on ClinicalTrials.gov More HIV Infections trials